Which statement is true about GSM treatment?

Which statement is true about GSM treatment?

• A. Vaginal estrogen is contraindicated in GSM.
• B. GSM cannot be treated effectively.
• C. Systemic therapy is always required for GSM.
• D. Vaginal estrogen is recommended for GSM.

Answer: (D)

GSM stems from estrogen deficiency after menopause, which thins and dries the vaginal and urethral tissues and leads to symptoms such as dryness, irritation, and uncomfortable intercourse. Applying low-dose estrogen directly to the vaginal area nourishes and thickens the mucosa, increases lubrication, and restores elasticity, all with minimal systemic absorption. This targeted effect makes vaginal estrogen a recommended first-line therapy for GSM in most patients, providing meaningful relief without mandating systemic treatment. The statements that vaginal estrogen is contraindicated, that GSM cannot be treated, or that systemic therapy is always required are not accurate in typical clinical scenarios; local vaginal estrogen is generally appropriate and effective for GSM.

GSM stems from estrogen deficiency after menopause, which thins and dries the vaginal and urethral tissues and leads to symptoms such as dryness, irritation, and uncomfortable intercourse. Applying low-dose estrogen directly to the vaginal area nourishes and thickens the mucosa, increases lubrication, and restores elasticity, all with minimal systemic absorption. This targeted effect makes vaginal estrogen a recommended first-line therapy for GSM in most patients, providing meaningful relief without mandating systemic treatment. The statements that vaginal estrogen is contraindicated, that GSM cannot be treated, or that systemic therapy is always required are not accurate in typical clinical scenarios; local vaginal estrogen is generally appropriate and effective for GSM.